REGENERON PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $82.90B
- P/E (TTM)
- 19.3
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | $4.30B | $12.23 | $14.29 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | Before market open | $3.60B | $6.75 | $9.47 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 30, 2026 | Before market open | $3.90B | $7.86 | $11.44 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | Before market open | $3.75B | $13.62 | $11.83 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 1, 2025 | Before market open | $3.68B | $12.81 | $12.89 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 29, 2025 | Before market open | $3.03B | $7.27 | $8.22 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 4, 2025 | Before market open | $3.79B | $8.06 | $12.07 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $3.72B | $11.54 | $12.46 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 2, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | 2026 | $1.03B to $1.10B | Lowered |
| GAAP gross margin on net product salesGAAP | 2026 | 78% to 79% | Raised |
| Non-GAAP gross margin on net product sales (a)non-GAAP | 2026 | 84% to 85% | Raised |
| Non-GAAP SG&A (a)non-GAAP | 2026 | $2.50B to $2.60B | Lowered |
| GAAP effective tax rateGAAP | 2026 | 13% to 14% | Raised |
| Non-GAAP effective tax rate (a)non-GAAP | 2026 | 14% to 15% | Raised |
| Non-GAAP R&D (a)non-GAAP | 2026 | $5.95B to $6.05B | Raised |
| GAAP R&DGAAP | 2026 | $6.50B to $6.64B | Raised |
| GAAP SG&AGAAP | 2026 | $2.83B to $2.96B | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Regeneron Pharmaceuticals filed with the SEC
Regeneron Reports Second Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports First Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
J a n u a r y 1 2 , 2 0 2 6
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Regeneron Reports Third Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Second Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports First Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion
Results of operations · Other events · EX-99.1 to Form 8-K
Business Updates and Highlights from Broad Clinical Pipeline at the 43 rd Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
J.P. Morgan Healthcare Conference JANUARY 13, 2025 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Regeneron Reports Third Quarter 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Second Quarter 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports First Quarter 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
J.P.Morgan Healthcare Conference JANUARY 8, 2024 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Second Quarter 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports First Quarter 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
J.P. Morgan Healthcare Conference January 9, 2023 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Regeneron Reports Third Quarter 2022 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Second Quarter 2022 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports First Quarter 2022 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
JP Morgan Healthcare Conference 2022 January 2022 This non - promotional presentation is intended for the investor audience and contains investigational data as well as forward - loo king statements; actual results may vary materially
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Regeneron Reports Third Quarter 2021 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K